Sartorius Stedim Biotech (SSB) and Refine Technology have entered into a collaboration to develop a robust platform for high-density cell cultivation. The goal of the platform is enable fast, easy connection of Refine’s ATF System with SSB’s single-use BIOSTAT bioreactors.

“We decided to work together, based on market feedback, to create a better platform for late-stage clinical and commercial-scale biopharmaceutical manufacturing processes. Our objective is to give our customers the confidence of a well-thought-out system featuring optimal and robust high-density cell cultivation via perfusion and concentrated fed-batch processes,” said Christel Fenge, vice president of Fermentation Technologies at SSB.

“The market demand for cell retention systems is expanding rapidly and we are pleased to be working with SSB to ensure that the ATF System integrates effortlessly with the BIOSTAT bioreactors. Our objective is to dramatically reduce the risk and cost of upstream processing through continuous culture and process intensification,” said John Bonham-Carter, vice president of sales and business development at Refine.